FinTechFunding

Vivace Therapeutics: Raises $30M in Series C Financing

  • Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company, closed a $30m Series C financing
  • The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners
  • In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace
  • The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP
  • Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway
  • The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need
Previous article
Aceable: Raises $50M in Growth Funding
Next article
Very Good Security: Raises $60M in Series C Funding
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Swedish Court Delays Judgment in Klarna’s Antitrust Case Against Google

The court's decision is crucial for Klarna's operations in the competitive market.Highlights: Swedish court delays decision on Klarna's...
FinTech

Morgan Stanley Launches Bitcoin ETF, Expanding Crypto Offerings

The investment firm broadens its reach into the cryptocurrency market.Highlights: Morgan Stanley launches a Bitcoin ETF to enhance...
FinTech

HSBC Strengthens Position with Hong Kong Stablecoin Issuer License

The banking giant aims to support digital asset initiatives in the region.Highlights: HSBC receives a stablecoin issuer license...
FinTech

US Treasury Secretary Warns Banks About Anthropic’s New AI Model

Treasury Secretary highlights risks AI poses to financial stability.Highlights: US Treasury Secretary warns banks about the risks of...